Hornuß Daniel, Rieg Siegbert
Klinik für Innere Medizin II, Abteilung Infektiologie, Universitätsklinikum Freiburg, Hugstetter Str. 55, 79106, Freiburg, Deutschland.
Inn Med (Heidelb). 2023 Apr;64(4):351-361. doi: 10.1007/s00108-023-01490-5. Epub 2023 Mar 14.
Allergic reactions to antibiotics belong to hypersensitivity drug reactions and can trigger both immunoglobulin E-mediated symptoms and T cell-mediated symptoms. Skin manifestations are the most common symptoms. Although reporting a penicillin allergy results in considerable restrictions in the treatment of acute infections, which may be associated with poor treatment outcomes, in most cases the label 'penicillin allergy' is not called into question or critically reviewed. However, in 85-90% of patients, 'penicillin allergy' constitutes a mislabeling of a non-specific intolerance reaction that does not pose a risk to the patient when re-exposed to penicillins. Careful history taking, an evaluation of manifestations in the past, and easy-to-perform initial diagnostic steps are crucial in differentiating non-specific intolerance reactions from penicillin allergy sensu stricto. Thus, a penicillin de-labeling strategy allows for optimized antibiotic therapy in the event of a future infection. Although allergic cross-reactivity between different β‑lactam antibiotics can occur, the risk for a severe cross-reactivity is dependent on chemical properties of the specific β‑lactam. Published cross-reactivity tables can help in risk stratification and choice of alternative β‑lactam agents.
抗生素过敏反应属于药物超敏反应,可引发免疫球蛋白E介导的症状和T细胞介导的症状。皮肤表现是最常见的症状。尽管报告青霉素过敏会导致急性感染治疗受到相当大的限制,这可能与治疗效果不佳有关,但在大多数情况下,“青霉素过敏”这一标签不会受到质疑或严格审查。然而,在85%至90%的患者中,“青霉素过敏”是对非特异性不耐受反应的错误标记,当患者再次接触青霉素时,这种反应对患者并不构成风险。仔细询问病史、评估既往表现以及易于实施的初始诊断步骤对于区分非特异性不耐受反应和严格意义上的青霉素过敏至关重要。因此,青霉素去标签策略能够在未来发生感染时实现优化的抗生素治疗。尽管不同的β-内酰胺类抗生素之间可能会发生过敏交叉反应,但严重交叉反应的风险取决于特定β-内酰胺的化学性质。已发表的交叉反应表有助于进行风险分层和选择替代β-内酰胺类药物。